Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12609000295246
ACTRN12609000295246
Completed
Phase 4

Investigation of Genetic Predictors of the Response to Selective Serotonin Re-Uptake Inhibitors (SSRI) Treatment in individuals suffering from major depression

Tartu University0 sites135 target enrollmentMay 18, 2009
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsDepressionAntidepressantTreatment predictionMental Health - Depression

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Depression
Sponsor
Tartu University
Enrollment
135
Status
Completed
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 18, 2009
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Tartu University

Eligibility Criteria

Inclusion Criteria

  • •Both genders
  • •Major Depression diagnosis according to Diagnostic and Statistical Manual of Mental Disorders (DSM\-IV) criteria
  • •At severity of depression of at least moderate as indicated by a Montgomery\-Asberg's Depression Rating Scale (MADRS) total score of 22 or higher
  • •Only secondary current comorbid anxiety disorder

Exclusion Criteria

  • •Bipolar disorder
  • •Psychotic disorder or features
  • •Current eating disorders
  • •Mental retardation
  • •Any pervasive developmental disorder or cognitive disorder
  • •Alcohol or drug abuse\-related disorders within 12 months prior to baseline
  • •Acute infections, neurological or any other unstable general disorders, serious suicide risk, formal behaviour therapy, or systematic psychotherapy, pregnancy or breastfeeding
  • •A history of hypersensitivity or non\-response to escitalopram

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, Not Recruiting
N/A
Investigation of genetic predictors of the response to SSRI treatment in patients with panic disorderpanic disorder
EUCTR2007-002649-19-EETartu University Hospital Psychiatry Clinic500
Completed
N/A
Exploratory Study of Genetic Factors Related to the Inhibitory Effect of Tolvaptan on Increased Kidney Volume in Patients with Autosomal Dominant Polycystic Kidney DiseaseAutosomal Dominant Polycystic Kidney Disease
JPRN-UMIN000031976Otsuka Pharmaceutical Co.,Ltd.890
Not Yet Recruiting
N/A
Genetics of margin-negative Oral Squamous Cell Carcinoma surgical resection.
CTRI/2023/11/060253ICMR
Recruiting
N/A
Genetic analysis of prognosis-related factors in gliomas: methylation of MGMT, LOH of 1p/19q, and mutation of IDH1/2.Glioma
JPRN-UMIN000003196Yokohama City University of Medicine100
Recruiting
N/A
The study of investigating the genetic profiles of Exceptional Response in cancer therapies.Cancer patient who received therapies.
JPRN-UMIN000016643ational Cancer Center Hospital30